Clinical trials: Atopic Dermatitis Eczema
Moderate to Severe Atopic Dermatitis
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT07370909
- Testing
- LW402
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
Chronic Hand Eczema
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema.
- Trial name
- NCT03683719
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 28 sites in United States, Denmark and 1 more
- Volunteers
- 258 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04033367
- Testing
- Dupilumab
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants
This is a randomised, double-blinded, placebo-controlled first in human (FIH) trial to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of GB-7624.
- Trial name
- NCT06920693
- Testing
- GB-7624
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Generate Biomedicines
Eczema, Atopic Dermatitis
Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic…
- Trial name
- STREAM-AD (NCT05131477)
- Testing
- Amlitelimab
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 390 people
- Sponsor
- Kymab Limited
Atopic Dermatitis, Atopic Dermatitis Eczema
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
- Trial name
- NCT06024499
- Testing
- HY209GEL Active
- Where
- 12 sites in United States, South Korea
- Volunteers
- 210 people
- Sponsor
- Shaperon
Atopic Dermatitis
Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates
Atopic dermatitis is a chronic disease, with outbreaks, predominant in childhood, whose main symptom is pruritus of variable intensity and signs of cutaneous xerosis and eczematous pattern lesions.
- Trial name
- LB2001 (NCT04271007)
- Testing
- Mometasone Furoate
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- Libbs Farmacêutica LTDA
Atopic Dermatitis
Evaluation of the Efficacy of a Dermocosmetic Product RT00401-GO0046 on Atopic Dermititis Severity in Subjects With Mild Atopic Dermatitis Versus Placebo
The aim of this study is to evaluate the RT00401- GO0046 formula on atopic dermititis severity in subjects with mild atopic dermatitis versus placebo on 26 subjects.
- Trial name
- NCT06763939
- Testing
- RT00401-GO0046, RT00401-GA0677
- Where
- Poland
- Volunteers
- 32 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis
The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult participants with atopic dermatitis.
- Trial name
- NCT00717769
- Testing
- SUN13834
- Where
- 28 sites in United States
- Volunteers
- 270 people
- Sponsor
- Daiichi Sankyo
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
- Trial name
- NCT06787586
- Testing
- ATTO-1310
- Where
- 17 sites in United States, Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Atopic Dermatitis
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
- Trial name
- NCT03058783
- Testing
- IDP-124 Lotion, IDP-124 Vehicle Lotion
- Where
- United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Severe Atopic Dermatitis (AD)
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
This study is researching an approved drug called dupilumab (called "study drug"). Dupilumab is approved in the United States for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe…
- Trial name
- BUILD-PEDS (NCT07187089)
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
- Trial name
- NCT06101823
- Testing
- OpSCF
- Where
- 22 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Insmed Incorporated
Atopic Eczema
Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser
Topical steroid creams as well as moisturizing creams are important parts of the treatment strategy of atopic eczema. This study aims to investigate the tolerance of a new strong steroid cream in comparison to an already marketed…
- Trial name
- NCT00576238
- Testing
- betamethasone valerate, urea
- Where
- 5 sites in Sweden
- Volunteers
- 55 people
- Sponsor
- ACO Hud Nordic AB
Atopic Dermatitis (AD)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
This is an operationally seamless Phase II/III, multicenter, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07784816
- Testing
- TLL-018 tablets
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Alopecia Areata, Vitiligo
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
- Conditions
- Alopecia Areata, Vitiligo, Atopic Dermatitis, Psoriasis
- Trial name
- Derma-001 (NCT06319781)
- Testing
- Observational
- Where
- 3 sites in Denmark
- Volunteers
- 370 people
- Sponsor
- Blueskin AS
Atopic Dermatitis, Psoriasis
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
- Trial name
- NCT05718921
- Testing
- YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.